Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. announced the termination of its agreement with a former financial advisor on November 3, 2026. The original agreement stipulated potential payments of up to $2.0 million in cash and $2.0 million in stock tied to the closing of specific business combinations. As part of the termination settlement, Matinas BioPharma paid the advisor $562,500 in cash, and both parties have executed mutual releases, contingent on certain conditions.

Matinas BioPharma Holdings, Inc. reported a net loss of $(1.326) million for the second quarter of 2026 and $(3.247) million for the first six months of 2026. With cash and cash equivalents of $761 thousand and an accumulated deficit of $214.034 million as of June 30, 2026, the company issued a going concern warning. Subsequent to the quarter, Matinas entered into a Business Combination Agreement with GH Power Inc. and a Stock Purchase Agreement to sell its Nanotechnologies subsidiary. The company also secured additional funding through a Series D Financing and a Warrant Inducement, raising $575 thousand and $2.323 million, respectively.

Matinas BioPharma Holdings, Inc. announced the termination of its At-The-Market Sales Agreement with BTIG, LLC. BTIG notified the company of the immediate termination on July 23, 2026, in accordance with the agreement's terms. The original agreement, established in July 2020, allowed Matinas BioPharma to offer and sell up to $50 million of its common stock through BTIG. The company will not incur any termination penalties or related expenses.

Matinas BioPharma Holdings, Inc. announced a definitive business combination agreement with GH Power Inc. to create a new NYSE-listed critical minerals and clean energy company, GHP International. Concurrently, Matinas will sell its Matinas BioPharma Nanotechnologies, Inc. subsidiary, including MAT2203 and the LNC technology platform, to Azurity Pharmaceuticals for $4.0 million upfront, up to $17.5 million in potential milestones, and future royalties. Additionally, Matinas completed financings, raising $575,000 from a PIPE and approximately $2.6 million from a warrant inducement, with proceeds intended for working capital.

Matinas BioPharma Holdings, Inc. announced it received a notice from NYSE American for non-compliance with continued listing standards, specifically regarding stockholders' equity falling below required thresholds of $4.0 million and $6.0 million, and sustained losses over five fiscal years. As of March 31, 2026, stockholders' equity was $3.02 million. However, NYSE American has accepted the Company's plan to regain compliance and granted a plan period through October 2, 2027, allowing its shares to continue trading during this time.

Matinas BioPharma reported a net loss of $(1.92) million for Q1 2026, an increase from $(1.66) million in Q1 2025. The company's cash and cash equivalents significantly decreased by 40% to $2.40 million as of March 31, 2026, leading to a "substantial doubt" about its ability to continue as a going concern. The company is focused on monetizing MAT2203, conserving cash, and exploring strategic options like partnerships or a merger.